Development, Validation and Results of Quantitative Stability Testing for Gastrografin<sup>®</sup>

ISSN: 1875-676X (Online)
ISSN: 1573-4129 (Print)


Volume 10, 4 Issues, 2014


Download PDF Flyer




Current Pharmaceutical Analysis

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK
Email: cpa@benthamscience.org

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 0.771
5 - Year: 1.107

Development, Validation and Results of Quantitative Stability Testing for Gastrografin®

Author(s): Neera Naidoo, Ryash Vather, Noble Kuntworbe, Ian Bissett and Gil Hardy

Affiliation: vAnQual Laboratories, School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland Mail Centre 1142, New Zealand.

Abstract

Introduction: Gastrografin® is a commercially available contrast agent, primarily utilised in abdominal computed tomography. In order to conduct a randomised controlled clinical trial to determine whether gastrografin® may confer a therapeutic benefit in a postoperative ileus it was necessary to ensure that re-packaging of gastrografin® during blinding had no effect on the stability of its active diatrizoate salts (DTZ).

Aim: To develop a validated and rapid reverse phase High Performance Liquid Chromatography (HPLC) analytical method for the assay of DTZ that could then be utilised to determine the stability of gastrografin®.

Methods: A published HPLC method for meglumine amidotrizoate injection was adapted and validated for the stability studies. These were carried out in accordance with ICH guidelines.

Results: The HPLC method was validated for specificity (no elution peak with placebo), linearity (r2=0.999), accuracy (≤5%) and precision (≤3%). Gastrografin® exposed to 25ºC and 60% relative humidity remained stable for 30 days with no physical change to the solution. Gastrografin® stored under identical conditions and exposed to 1.2 million lux hours of light remained stable for 7 days. Gastrografin® stored at 4ºC underwent crystallisation; this was readily reversed by agitation and had no discernible effect on 30-day drug stability.

Conclusion: Gastrografin® remains stable and active for a minimum of 30 days under standard storage conditions (25ºC, 60% humidity, no light) after re-packaging.


Keywords: Gastrografin, diatrizoate, stability testing.

Purchase Online Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 10
Issue Number: 2
First Page: 92
Last Page: 96
Page Count: 5
DOI: 10.2174/1573412910999140113120243
Advertisement

Related Journals


Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science